Research and development spending rose approximately $11.3 million to $19.6 million, reflecting higherInvestmentin the company’s development programs.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) may sell up to $500,000,000 of common stock through TD Cowen, acting as agent or principal. The at-the-market program allows sales from time to time at prices and on terms determined by market conditions. The actual number of shares …
Pluri Inc. (NASDAQ: PLUR) agreed to sell 1,200,000 common shares and pre-funded warrants for up to 1,028,940 additional common shares in a registered direct offering. The shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.49999. Pluri expects approximately $2,984,808 …
Roivant Sciences gained U.S. FDA approval for LISRAYA to treat adults with dermatomyositis, with a wholesaleAcquisitioncost of $35,000 for a 30-count bottle of 30 mg tablets. Investors now have a disclosed regulatory milestone and a stated wholesale price for the treatment.Key HighlightsRoivant posted an …
SANGAMO THERAPEUTICS, INC (OTC: SGMOQ). Agreed to sell assets tied primarily to ST-920, its one-time administered AAV gene therapy candidate for Fabry disease, to PTC Therapeutics for $111,000,000 in cash at closing.
Shuttle Pharmaceuticals facesNasdaqnoncompliance under Listing Rule 5250(c)(1) after delaying its Form 10-Q for the period ended June 30, 2026. The common stock remains listed and tradable for now, but failure to regain compliance could lead to delisting, while the company must submit a corrective …
Arrangement Provides Access to Common-Stock Sales
Bone Biologics Corp (NASDAQ: BBLGW) will ask shareholders to vote on six proposals at its annual meeting on September 28, 2026, including potential common stock issuance tied to certain warrants and a proposed reverse stock split. The meeting was postponed from August 11, 2026. …
Bone Biologics Corp (NASDAQ: BBLGW) will put a potential reverse stock split before shareholders at its annual meeting on September 28, 2026. The proposed ratio ranges from 1-for-2 to 1-for-10, with the Board holding discretion over the final ratio.
Kevin J. O'Donnell, CEO and Director of Eightco Holdings Inc. (NASDAQ:ORBS), filed a Form 4 on August 31, 2026, disclosing the open-market purchase of 50,000 shares of common stock on August 28, 2026.